Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qomel CoSAU:9600 +2.08%22 ROE % is 8.32% as of Dec. 2025, which is 71% below its 10-year median of 29.18. GuruFocus rates SAU:9600 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 622 Healthcare Providers & Services companies, Qomel Co ranks better than 71.54% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Qomel Co's annualized net income for the quarter that ended in Dec. 2025 was ﷼9.8 Mil. Qomel Co's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was ﷼117.5 Mil. Therefore, Qomel Co's annualized ROE % for the quarter that ended in Dec. 2025 was 8.32%.
The historical rank and industry rank for Qomel Co's ROE % or its related term are showing as below:
SAU:9600'
s ROE % Range Over the Past 10 Years
Min: 13.2 Med: 29.18 Max: 38.67
Current: 13.2
During the past 3 years, Qomel Co's highest ROE % was 38.67%. The lowest was 13.20%. And the median was 29.18%.
SAU:9600's ROE % is ranked better than 71.54% of 622
companies
in the Healthcare Providers & Services industry
Industry Median: 5.895
vs SAU:9600: 13.20
Qomel Co (SAU:9600) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Qomel Co ROE % Related Terms
Qomel Co ROE % Historical Data
* Premium members only.
The historical data trend for Qomel Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Qomel Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qomel Co ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qomel Co's ROE % distribution charts can be found below:
* The bar in red indicates where Qomel Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Qomel Co (SAU:9600) has a ROE % of 8.32% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Qomel Co and its competitors. This is 71% below median its historical median of 29.18. Over the past decade, Qomel Co's ROE % has ranged from 13.20 to 38.67. According to the industry distribution chart, Qomel Co ranks #177 out of 622 companies in the Healthcare Providers & Services industry, placing it in the top 28.5%.
Is Qomel Co's ROE % too high?
Qomel Co's current ROE % of 8.32% is 71% below median its 10-year median of 29.18. Over the past 10 years, this metric has ranged from a low of 13.20 to a high of 38.67. The Healthcare Providers & Services industry median ROE % is 5.90. Qomel Co's value of 8.32% is 41.1% above this industry median. Based on the distribution chart, Qomel Co ranks #177 out of 622 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Qomel Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Qomel Co's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qomel Co ranks #177 out of 622 companies for ROE %. This puts Qomel Co in the upper half of its industry. The industry median ROE % is 5.90. Qomel Co's value of 8.32% is 41.1% above this benchmark. Historically, Qomel Co's own ROE % has ranged from 13.20 to 38.67 over the past decade. While the company's 10-year median is 29.18 vs. the industry median of 5.90, Qomel Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.90, based on 622 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qomel Co's current ROE % of 8.32% is 41.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Qomel Co and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qomel Co's current ROE % is 8.32%, which is 71% below median its own 10-year median of 29.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qomel Co stock overvalued right now?
Qomel Co (SAU:9600) has a current ROE % of 8.32%. The current ROE % is 8.32%, which is 71% below median its 10-year median of 29.18 and 41.1% above the Healthcare Providers & Services industry median of 5.90. Qomel Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Qomel Co (SAU:9600), the current ROE % is 8.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qomel Co is a Saudi Arabian-based healthcare company that provides high-quality medicines and innovative medical services whose core business focuses on institutional and government supply through a professional field force and an in-depth knowledge of the local business environment They offer services such as pharmaceutical and medical supplies.
22GF Score
Get the complete analysis for SAU:9600
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9600 has been successfully added to your 
